Title:
Clinical Abacavir Hypersensitivity Reaction among Children in India

dc.contributor.authorJaya Chakravarty
dc.contributor.authorSaurabh Sharma
dc.contributor.authorAnuradha Johri
dc.contributor.authorAnkita Chourasia
dc.contributor.authorShyam Sundar
dc.date.accessioned2026-02-07T08:16:23Z
dc.date.issued2016
dc.description.abstractAbacavir is currently recommended as a part of first line regimen by National AIDS Control Organization. The objective of this study was to observe the incidence of clinically diagnosed abacavir Hypersensitivity reaction (HSR) among children on abacavir based therapy in the National program. In this observational study, all children started on abacavir were included and HSR reaction was diagnosed clinically as per National guidelines. HLA- B*5701 testing was done in children diagnosed with clinical abacavir HSR. Among 101 children started on abacavir during the study period, 8 [7.9 % (95 % CI 3.5-15.0 %)] children developed clinically diagnosed abacavir HSR. All children with concomitant illness (4/8) were HLA-B*5701 negative. Only 2 (25 %, 2/8) carried HLA-B*5701 allele. Fever with abdominal symptoms as compared to respiratory symptoms were more common in HLA-B*5701 positive cases. Overdiagnosis of clinically diagnosed abacavir HSR is common and could be decreased by treating concomitant illness before starting abacavir. © 2016, Dr. K C Chaudhuri Foundation.
dc.identifier.doi10.1007/s12098-016-2044-z
dc.identifier.issn195456
dc.identifier.urihttps://doi.org/10.1007/s12098-016-2044-z
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/29000
dc.publisherSpringer India
dc.subjectAbacavir
dc.subjectAntiretroviral therapy
dc.subjectHIV
dc.subjectHLA-B*5701
dc.subjectHypersensitivity reaction
dc.titleClinical Abacavir Hypersensitivity Reaction among Children in India
dc.typePublication
dspace.entity.typeArticle

Files

Collections